Short description
Plexxikon is a engages in the discovery and development of small molecule pharmaceuticals to treat human disease.
Description
Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease.
The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease.
It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.
Last funding
No Way
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Berkeley, California, United States, North America
Founded on
January 1, 2000
Closed on
March 31, 2022
Exited on
February 28, 2011
Non-profit?
No
Acquired?
No
Employees count
51-100
Investors
Nopepepe, No Way, Uh Ohhhh, Nopepepe, Noaccessforu, Noaccess, Noaccessforu
Sign in for full access
Founders
Joseph Schlessinger, Peter Hirth, Sung-Hou Kim